The Evaluation and Treatment of Graves Ophthalmopathy

Medical Clinics of North America

Volumn 96, Issue 2, 2012, Pages 311-328

  Stan, Marius N ^a   Garrity, James A ^a   Bahn, Rebecca S ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Graves disease; Graves ophthalmopathy; Radioactive iodine; Thyrotropin receptor autoantibodies

Indexed keywords

ALLOPURINOL; ANTITHYROID AGENT; ARTIFICIAL TEAR; AZATHIOPRINE; BOTULINUM TOXIN A; CORTICOSTEROID; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOGLOBULIN; LEVOTHYROXINE; METHYLPREDNISOLONE; NICOTINAMIDE; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; RADIOACTIVE IODINE; RITUXIMAB; SELENIUM; SOMATOSTATIN DERIVATIVE; THIAMAZOLE; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY;

ADRENAL INSUFFICIENCY; AGE; CHEMOSIS; CIGARETTE SMOKING; CLINICAL ACTIVITY SCORE; CLINICAL ASSESSMENT TOOL; COLD TREATMENT; COMPRESSION THERAPY; CONJUNCTIVA DISEASE; CONJUNCTIVAL ERYTHEMA; CORNEA ULCER; CORTICOSTEROID THERAPY; CUSHING DISEASE; DEPRESSION; DIABETES MELLITUS; DIPLOPIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DYSTHYROID OPTIC NEUROPATHY; ENDOCRINE OPHTHALMOPATHY; ERYTHEMA; EXOPHTHALMOS; EYELID DISEASE; EYELID ERYTHEMA; EYELID SWELLING; GASTROINTESTINAL SYMPTOM; GAZE; GLUCOSE BLOOD LEVEL; GRAVES DISEASE; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INTRAOCULAR PRESSURE; KIDNEY FAILURE; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; MYALGIA; OPTIC NERVE DISEASE; ORBIT INFLAMMATION; ORBIT TUMOR; ORBITAL RADIOTHERAPY; OSTEOPOROSIS; PASSIVE SMOKING; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RADIATION RETINOPATHY; RADIOISOTOPE THERAPY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHABILITATION; RETINOPATHY; REVIEW; RISK FACTOR; SERUM SICKNESS; SIDE EFFECT; SMOKING CESSATION PROGRAM; SOMNOLENCE; SWELLING; THYROIDECTOMY; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; DECOMPRESSION, SURGICAL; DISEASE PROGRESSION; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOSPHODIESTERASE INHIBITORS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84858758074     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.01.014     Document Type: Review

References (94)

1. Bahn R.S. Graves' ophthalmopathy. N Engl J Med 2010, 362:726-738.
2. Khoo D.H., Eng P.H., Ho S.C., et al. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 2000, 10:1093-1100.
3. Wiersinga W.M., Smit T., van der Gaag R., et al. Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease. J Endocrinol Invest 1988, 11:615-619.
4. Rundle F.F., Wilson C.W. Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy. Clin Sci 1945, 5:177-194.
5. Perros P., Crombie A.L., Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol 1995, 42:45-50.
6. Bahn R.S. Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 2003, 88:1939-1946.
7. Wiersinga W.M. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?. J Clin Endocrinol Metab 2011, 96:2386-2394.
8. van Zeijl C.J., Fliers E., van Koppen C.J., et al. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways. Thyroid 2011, 21:169-176.
9. Kumar S., Nadeem S., Stan M.N., et al. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. J Mol Endocrinol 2011, 46:155-163.
10. Rapoport B., Alsabeh R., Aftergood D., et al. Elephantiasic pretibial myxedema: insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves' disease. Thyroid 2000, 10:685-692.
11. Stan M.N., Bahn R.S. Risk factors for development or deterioration of Graves' ophthalmopathy. Thyroid 2010, 20:777-783.
12. Tunbridge W.M., Evered D.C., Hall R., et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol 1977, 7:481-493.
13. Wiersinga W.M., Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002, 12:855-860.
14. Enzmann D.R., Donaldson S.S., Kriss J.P. Appearance of Graves' disease on orbital computed tomography. J Comput Assist Tomogr 1979, 3:815-819.
15. Bartley G.B. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994, 92:477-588.
16. Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol 2005, 6:295-309.
17. Bartalena L., Baldeschi L., Dickinson A.J., et al. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 2008, 18:333-346.
18. Mourits M.P., Prummel M.F., Wiersinga W.M., et al. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol 1997, 47:9-14.
19. Wiersinga W.M., Perros P., Kahaly G.J., et al. Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006, 155:387-389.
20. Yeatts R.P. Quality of life in patients with Graves ophthalmopathy. Trans Am Ophthalmol Soc 2005, 103:368-411.
21. Terwee C.B., Gerding M.N., Dekker F.W., et al. Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998, 82:773-779.
22. Terwee C.B., Dekker F.W., Mourits M.P., et al. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol 2001, 54:391-398.
23. Jacobson E.M., Tomer Y. The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. J Autoimmun 2007, 28:85-98.
24. Tsai C.C., Kau H.C., Kao S.C., et al. Exophthalmos of patients with Graves' disease in Chinese of Taiwan. Eye 2006, 20:569-573.
25. Burch H.B., Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993, 14:747-793.
26. Davies T.F., Kendler D.L. Mechanisms of human autoimmune thyroid disease. Monogr Pathol 1993, (35):103-117.
27. Prummel M.F., Wiersinga W.M., Mourits M.P., et al. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 1990, 150:1098-1101.
28. Tallstedt L., Lundell G., Blomgren H., et al. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?. Eur J Endocrinol 1994, 130:494-497.
29. Kung A.W., Yau C.C., Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 1994, 79:542-546.
30. Baujat B., Krastinova D., Bach C.A., et al. Orbital morphology in exophthalmos and exorbitism. Plast Reconstr Surg 2006, 117:542-550. [discussion: 551-2].
31. Tallstedt L., Lundell G., Torring O., et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992, 326:1733-1738. [see comment].
32. Traisk F., Tallstedt L., Abraham-Nordling M., et al. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009, 94:3700-3707.
33. Pfeilschifter J., Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol 1996, 45:477-481.
34. Krassas G.E., Segni M., Wiersinga W.M. Childhood Graves' ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 2005, 153:515-520.
35. Eckstein A.K., Plicht M., Lax H., et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006, 91:3464-3470.
36. Gerding M.N., van der Meer J.W., Broenink M., et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol 2000, 52:267-271.
37. Bartalena L., Marcocci C., Bogazzi F., et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998, 338:73-78.
38. Perros P., Kendall-Taylor P., Neoh C., et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy. J Clin Endocrinol Metab 2005, 90:5321-5323.
39. Eckstein A., Quadbeck B., Mueller G., et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 2003, 87:773-776.
40. Bartalena L., Marcocci C., Tanda M.L., et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998, 129:632-635.
41. Prummel M.F., Wiersinga W.M. Smoking and risk of Graves' disease. JAMA 1993, 269:479-482.
42. Bartalena L., Marcocci C., Bogazzi F., et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989, 321:1349-1352.
43. Bahn R.S., Burch H.B., Cooper D.S., et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011, 20:593-646.
44. Baldeschi L., Wakelkamp I.M., Lindeboom R., et al. Early versus late orbital decompression in Graves' orbitopathy: a retrospective study in 125 patients. Ophthalmology 2006, 113:874-878.
45. Bahn R.S., Burch H.B., Cooper D.S., et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011, 17:456-520.
46. Lai A., Sassi L., Compri E., et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 2010, 95:1333-1337.
47. Uddin J.M., Davies P.D. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology 2002, 109:1183-1187.
48. Bouzas E.A., Karadimas P., Mastorakos G., et al. Antioxidant agents in the treatment of Graves' ophthalmopathy. Am J Ophthalmol 2000, 129:618-622.
49. Marcocci C., Kahaly G.J., Krassas G.E., et al. Selenium and the course of mild Graves' orbitopathy. N Engl J Med 2011, 364:1920-1931.
50. Zang S., Ponto K.A., Kahaly G.J. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011, 96:320-332.
51. Kahaly G.J., Pitz S., Hommel G., et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005, 90:5234-5240.
52. Macchia P.E., Bagattini M., Lupoli G., et al. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. J Endocrinol Invest 2001, 24:152-158.
53. Le Moli R., Baldeschi L., Saeed P., et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 2007, 17:357-362.
54. Marino M., Morabito E., Brunetto M.R., et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 2004, 14:403-406.
55. Marcocci C., Watt T., Altea M.A., et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol 2012, 166(2):247-253.
56. Bahn R. High-dose intravenous glucocorticoid therapy for Graves' ophthalmopathy: where are we now?. Thyroid 2012, 22:1-2.
57. Ebner R., Devoto M.H., Weil D., et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 2004, 88:1380-1386.
58. Kahaly G., Schrezenmeir J., Krause U., et al. Cyclosporin and prednisone versus prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986, 16:415-422.
59. Prummel M.F., Mourits M.P., Berghout A., et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989, 321:1353-1359.
60. Perros P., Weightman D.R., Crombie A.L., et al. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol 1990, 122:8-12.
61. Kahaly G., Pitz S., Muller-Forell W., et al. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol 1996, 106:197-202.
62. Baschieri L., Antonelli A., Nardi S., et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid 1997, 7:579-585.
63. Dickinson A.J., Vaidya B., Miller M., et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2004, 89:5910-5915.
64. Wemeau J.L., Caron P., Beckers A., et al. Octreotide (long-acting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005, 90:841-848.
65. Chang T.C., Liao S.L. Slow-release lanreotide in Graves' ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 2006, 29:413-422.
66. Stan M.N., Garrity J.A., Bradley E.A., et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab 2006, 91:4817-4824.
67. El Fassi D., Banga J.P., Gilbert J.A., et al. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009, 130:252-258.
68. Salvi M., Vannucchi G., Campi I., et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006, 154:511-517.
69. El Fassi D., Nielsen C.H., Hasselbalch H.C., et al. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006, 16:709-710.
70. Khanna D., Chong K.K., Afifiyan N.F., et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2010, 117:133-139. e132.
71. Heemstra K.A., Toes R.E., Sepers J., et al. Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol 2008, 159:609-615.
72. Bradley E.A., Gower E.W., Bradley D.J., et al. Orbital radiation for Graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2008, 115:398-409.
73. Prummel M.F., Mourits M.P., Blank L., et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993, 342:949-954.
74. Prummel M.F., Terwee C.B., Gerding M.N., et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 2004, 89:15-20.
75. Kahaly G.J., Rosler H.P., Pitz S., et al. Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000, 85:102-108. [see comment].
76. Marcocci C., Bartalena L., Bogazzi F., et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 1991, 14:853-860.
77. Gorman C.A., Garrity J.A., Fatourechi V., et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001, 108:1523-1534. [see comment], [erratum appears in Ophthalmology 2004;111(7):1306].
78. Gerling J., Kommerell G., Henne K., et al. Retrobulbar irradiation for thyroid-associated orbitopathy: double-blind comparison between 2.4 and 16 Gy. Int J Radiat Oncol Biol Phys 2003, 55:182-189.
79. Bartalena L., Marcocci C., Chiovato L., et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983, 56:1139-1144.
80. Marcocci C., Bartalena L., Tanda M.L., et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001, 86:3562-3567.
81. Ohtsuka K., Sato A., Kawaguchi S., et al. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy. Am J Ophthalmol 2003, 135:285-290.
82. Marcocci C., Bartalena L., Rocchi R., et al. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 2003, 88:3561-3566.
83. Wakelkamp I.M., Tan H., Saeed P., et al. Orbital irradiation for Graves' ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmology 2004, 111:1557-1562.
84. Menconi F., Marino M., Pinchera A., et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 2007, 92:1653-1658.
85. Jarhult J., Rudberg C., Larsson E., et al. Graves' disease with moderate-severe endocrine ophthalmopathy-long term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid 2005, 15:1157-1164.
86. Feldon S.E., Muramatsu S., Weiner J.M. Clinical classification of Graves' ophthalmopathy. Identification of risk factors for optic neuropathy. Arch Ophthalmol 1984, 102:1469-1472.
87. Wiersinga W.M., Prummel M.F. Graves' ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab 2002, 13:280-287.
88. Soares-Welch C.V., Fatourechi V., Bartley G.B., et al. Optic neuropathy of Graves disease: results of transantral orbital decompression and long-term follow-up in 215 patients. Am J Ophthalmol 2003, 136:433-441.
89. Wakelkamp I.M., Baldeschi L., Saeed P., et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol 2005, 63:323-328.
90. Wiersinga W.M. Management of Graves' ophthalmopathy. Nat Clin Pract Endocrinol Metab 2007, 3:396-404.
91. Baldeschi L., MacAndie K., Hintschich C., et al. The removal of the deep lateral wall in orbital decompression: its contribution to exophthalmos reduction and influence on consecutive diplopia. Am J Ophthalmol 2005, 140:642-647.
92. Cansiz H., Yilmaz S., Karaman E., et al. Three-wall orbital decompression superiority to 2-wall orbital decompression in thyroid-associated ophthalmopathy. J Oral Maxillofac Surg 2006, 64:763-769.
93. Mourits M.P., Koornneef L., Wiersinga W.M., et al. Orbital decompression for Graves' ophthalmopathy by inferomedial, by inferomedial plus lateral, and by coronal approach. Ophthalmology 1990, 97:636-641.
94. Boulos P.R., Hardy I. Thyroid-associated orbitopathy: a clinicopathologic and therapeutic review. Curr Opin Ophthalmol 2004, 15:389-400.